Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Approval Leads Lannett To Job Losses

US Firm Will Consolidate R&D Operation

Executive Summary

Around 80 more jobs are to go at Lannett, as the company reels from rival Amneal bagging US Food and Drug Administration approval for the company’s top seller.

You may also be interested in...



Lannett Adds NovoLog Biosimilar As It Writes Off $198m Of Value

With ambitions of $1bn of sales by 2025, Lannett is looking to bolster its top-line further by expanding its co-development pact with China’s HEC Group for insulin biosimilar products. Management discussed the goal as Lannett presented financial results, which included a significant pre-tax loss.

Lannett Aims For Financial Flexibility

To improve its financial flexibility by lowering its annual interest expenses and principal payments, Lannett has used a portion of its existing cash on hand to pay off its Term A Loan in full.

Amneal Focuses On Complex Generics As Revenues See Double-Digit Growth

After launching several high-value complex generic products in the last six months, Amneal aims to launch eight more complex generics by August 2021 to add “tremendous value” to its generics business. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel